Skip to content
Companies

Claris Biotherapeutics

Eye drop biologic for neurotrophic keratitis

Raised to date

$5.6M

of $5.6M offered across 2 Form D filings

Still open
$1
Investors
6
Last filed
Sep 22, 2025

About

Claris Biotherapeutics, Inc. is a pioneering biotechnology company dedicated to the development of innovative therapies specifically aimed at treating corneal diseases. With a particular focus on neurotrophic keratitis (NK), a rare and debilitating condition that can lead to significant vision loss, Claris is committed to addressing critical unmet medical needs in this niche area of ocular health.

Claris stands out by leveraging its proprietary technology platform based on recombinant human variant hepatocyte growth factor (dHGF), aiming to not only treat neurotrophic keratitis but also potentially other corneal conditions.

Funding

Feb 20252026
Now

$3.3M round, first sold Feb 2025: $3.3M sold, $1 still open

  • DebtFiled Sep 22, 2025Form D
    $2.3M/ $2.3M
  • DebtFiled Mar 7, 2025Form D
    $3.3M/ $3.3M

Product

CSB-001

Ocular Therapy

CSB-001 is a topical ocular biologic solution that harnesses the regenerative properties of recombinant human variant hepatocyte growth factor (dHGF). This product is specifically engineered to promote and expedite healing in the cornea, which is vital for restoring vision in patients suffering from corneal diseases.

  • Topical application for easy administration
  • Utilizes recombinant human variant hepatocyte growth factor (dHGF)
  • Designed to enhance corneal healing

Built for

Patients with neurotrophic keratitis

People on file